GLP-3
Triple GIP/GLP-1/glucagon agonist
Research overview
A triple-acting peptide on the GIP, GLP-1 and glucagon receptors, studied in models of metabolic signaling and energy balance.
What is not known: safety and effects in people are not established; research use only.
Descriptions reference published research areas for laboratory context only and are not claims of efficacy, safety, or intended use in humans or animals.
- Price
- $450 CAD
- Purity
- ≥98% (HPLC)
- Presentation
- 10 mg lyophilized vial
Order GLP-3
Orders are placed only from a verified research account. Request the certificate of analysis (COA) for the lot you receive.
Verified Canadian research buyers only · 21+
For laboratory research use only — not for human or veterinary use
GLP-3 is a chemical reference material sold strictly for in-vitro laboratory research by qualified professionals. It is not a drug, food, cosmetic, or natural health product; it has not been evaluated or approved by Health Canada; and it must never be ingested, injected, or applied to humans or animals. Sold in Canada only, to purchasers 21+. See our Research Use Policy.
Research encyclopedia
Everything the literature has studied.
For laboratory research use only — not for human or veterinary use. The content below summarizes published research context only. It is not medical advice, makes no therapeutic claims, and describes no intended use in humans or animals. These materials have not been evaluated or approved by Health Canada.
What it is
Synthetic triple agonist of the GIP, GLP-1, and glucagon receptors, investigated in models of metabolic signaling and energy balance.
Mechanism of action
Simultaneously activates three receptors: GLP-1 and GIP signaling reduce appetite and slow gastric emptying in experimental models, while the glucagon receptor component increases energy expenditure and mobilizes hepatic fat.
Research areas
- GIP, GLP-1 and glucagon receptor signaling
- Energy expenditure in experimental models
- Hepatic lipid metabolism in experimental models
Studied effects in research models
- Increased energy expenditure in rodent models
- Reduced food intake in rodent models
- Reduced hepatic fat in rodent models
Effects listed describe observations reported in laboratory or animal research models only — not outcomes claimed for humans or animals.
Assay readouts in related research
Discovery & background
Described in the early 2020s as an extension of the dual GIP/GLP-1 agonist design, adding glucagon-receptor agonism.
Considerations & limitations
Research use only. Not approved by Health Canada for human or veterinary use. Evidence is limited to in vitro and animal models; safety and effects in people are not established. Request the certificate of analysis (COA) for the lot you receive.
References
- [1]Jastreboff et al., 2023 — N Engl J Med; PMID: 37366315
- [2]Rosenstock et al., 2023 — Lancet; PMID: 37356446
- [3]Coskun et al., 2022 (pharmacology) — Cell Metab; PMID: 36228616
- [4]Sanyal et al., 2024 — Nat Med; DOI: 10.1038/s41591-024-03018-2
Verified researchers only
Create a research account to order GLP-3
A verified research account is required to order, along with a signed attestation that these materials are for laboratory research only — never for human or veterinary use.
All materials are for laboratory research use only — not for human or veterinary use.